Trials / Terminated
TerminatedNCT05720052
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
A Phase I/II Study to Evaluate the Safety and Efficacy of the MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- MingSight Pharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I/II, single-arm, multicenter, open-label study which is divided into two portions: Phase I is dose escalation portion, in which subjects with relapsed or refractory B-cell lymphoma will be enrolled except malignant lymphoblastic lymphoma (LBL) and Burkitt lymphoma. After the RP2D is identified, Phase II of subjects with relapsed or refractory mantle cell lymphoma who previously received ≥ 2 and ≤ 4 different chemotherapy and/or targeted drug therapy will be enrolled.
Conditions
- Relapsed or Refractory B-cell Lymphoma
- Diffuse Large B-cell Lymphoma (DLBCL)
- Follicular Lymphoma (FL)
- Mantle Cell Lymphoma (MCL)
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Marginal Zone Lymphoma (MZL)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MS-553 | MS-553 oral tablet BID x 28-days |
Timeline
- Start date
- 2023-02-06
- Primary completion
- 2023-11-28
- Completion
- 2023-11-28
- First posted
- 2023-02-09
- Last updated
- 2024-07-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05720052. Inclusion in this directory is not an endorsement.